Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
Version 2 2020-07-08, 09:06
Version 1 2020-01-17, 16:42
media
posted on 2020-07-08, 09:06 authored by Robert T. Naismith, Annette Wundes, Tjalf Ziemssen, Elzbieta Jasinska, Mark S. Freedman, Anthony J. Lembo, Krzysztof Selmaj, Ilda Bidollari, Hailu Chen, Jerome Hanna, Richard Leigh-Pemberton, Maria Lopez-Bresnahan, Jennifer Lyons, Catherine Miller, David Rezendes, Jerry S. Wolinsky, on behalf of the EVOLVE-MS-2 study groupThe above video abstract represents the opinions of
the authors. For a full list of declarations, including
funding and author disclosure statements, please see the full text online (see
“read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.
